Profil bibliographique

Ruth Plummer

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

666Publications signalées

14391Citations signalées

4Affiliations récentes

Institutions déclarées

Newcastle upon Tyne Hospitals NHS Foundation Trust Sir Bobby Robson Foundation Newcastle upon Tyne Hospital Newcastle University

Domaines associés

PARP inhibition in cancer therapyDNA Repair MechanismsColorectal Cancer Treatments and StudiesMelanoma and MAPK PathwaysCancer Genomics and Diagnostics

Publications récentes

Accès ouvert 2026 articleOpenAlex

Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318

Hans Prenen, Sylvie Rottey, David J. Pinato, Thierry Lesimple et autres

0 citationsJournal for ImmunoTherapy of Cancer

Accès ouvert 2026 articleOpenAlex

Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework

Paulina Czajka‐Francuz, Chris Twelves, James Spicer, Archana Munje et autres

0 citationsBritish Journal of Cancer

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S1 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer

Martha L. Serrano‐Serrano, Christina Godfried Sie, Oliver Bechter, G. Pretelli et autres

0 citations

Accès ouvert 2026 otherOpenAlex

Figure 2 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer

Martha L. Serrano‐Serrano, Christina Godfried Sie, Oliver Bechter, G. Pretelli et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S10 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer

Martha L. Serrano‐Serrano, Christina Godfried Sie, Oliver Bechter, G. Pretelli et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S14 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer

Martha L. Serrano‐Serrano, Christina Godfried Sie, Oliver Bechter, G. Pretelli et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S4 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer

Martha L. Serrano‐Serrano, Christina Godfried Sie, Oliver Bechter, G. Pretelli et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S3 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer

Martha L. Serrano‐Serrano, Christina Godfried Sie, Oliver Bechter, G. Pretelli et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S5 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer

Martha L. Serrano‐Serrano, Christina Godfried Sie, Oliver Bechter, G. Pretelli et autres

0 citations

Accès ouvert 2026 otherOpenAlex

Data from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer

Martha L. Serrano‐Serrano, Christina Godfried Sie, Oliver Bechter, G. Pretelli et autres

0 citations

Accès ouvert 2026 otherOpenAlex

Figure 3 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer

Martha L. Serrano‐Serrano, Christina Godfried Sie, Oliver Bechter, G. Pretelli et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S7 from Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer

Martha L. Serrano‐Serrano, Christina Godfried Sie, Oliver Bechter, G. Pretelli et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.